Mumps IgM Screen EIA: Cat. No: MuVM004

Intended Use:

Enzyme Immunoassay (EIA) for the detection of human IgM antibodies to mumps virus in serum, plasma and oral fluid specimens.

Test Principle

In the Microimmune Mumps IgM capture EIA, undiluted, oral fluid extracted from a collection device(e.g. "Oracol" or "OraSure") or diluted serum / plasma is added to anti-human IgM coated microtitre wells. IgM in the specimen binds to the wells and after washing, recombinant mumps nucleoprotein (rMuNP) antigen is added. Mumps specific IgM in the sample, if present, binds the rMuNP. After washing the wells, a monoclonal antibody to the rMuNP conjugated to horseradish peroxidase is added. After washing, tetramethylbenzadine (TMB) substrate is added to reveal the presence of specific IgM. The presence of mumps specific IgM results in a colour change in the TMB from colourless to blue and then yellow on terminating the enzymatic reaction. The colour change and intensity is monitored using a spectrophotometric plate reader set at 450nm with a correction filter between 620 and 650nm. The presence of mumps specific IgM is indicated by optical density values above the cut-off.

Features of the Mumps IgM Screen EIA include:

• Assay time: < 2 h
• Specimen type: oral fluid, serum / plasma
• Reagents: Colour coded and mostly ready to use.
• Shelf life: 12 months at 2..8°C
• *Sensitivity of the Microimmune Mumps IgM capture EIA on serum samples compared to a IgM capture radioimmunoassay (MACRIA): 94.7% (95% CI 86.9 to 98.5%)
• *Sensitivity on serum / oral fluid pairs: 100%
• *Specificity of MI test on serum samples compared to MACRIA: 95.9% (95% CI 88.6 to 99.2%)
• *Specificity on serum oral / fluid pairs: 95.5%

*A detailed description of the evaluation of the test is given in the product insert.

Discounts on bulk purchases.  Please contact us directly by fax/ e-mail or phone for further information.